February 14th 2025
Zalevsky shares insights into the implications of the designation and what it may mean for Rezpeg's development timeline.
February 12th 2025
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Revolutionizing Atopic Dermatitis (RAD) Conference 2025
June 6-7, 2025
Register Now!
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis
View More
Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?
View More
Positive Results Reported in Roflumilast 0.15% for AD Across Diverse Populations
September 27th 2024“It is critical that our clinical data represent the diversity in the world around us, and these results further reinforce our commitment to providing meaningful innovation for immune-mediated skin diseases," said Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis.
Upadacitinib Demonstrates Efficacy in Patients With AD and Head and Neck Involvement
September 26th 2024Kilian Eyerich, MD, PhD, shares insights into an EADV 2024 presentation on upadacitinib’s ability to achieve almost total skin clearance in the head and neck regions with minimal effect on quality of life.
Optimizing MOAs of JAK Inhibitors in a 36-Year-Old Male With a History of Atopic Dermatitis
August 20th 2024Jayme Heim, MSN, FNP-BC, explores strategies for optimizing the mechanisms of action of topical JAK inhibitors in treating a 36-year-old male patient with a history of atopic dermatitis, highlighting the potential benefits and considerations of this therapeutic approach.